A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the pharmacokinetics of PF-06273588 following administration of a micro-dose via both intravenous and oral routes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men

NCT07015918

Healthy Male Volunteers

COMPLETED PHASE1

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

NCT06392230

Healthy Participants

COMPLETED PHASE1

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

NCT05652647

Healthy Participants

COMPLETED PHASE1

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

NCT02766621

Healthy

COMPLETED PHASE1

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

NCT03448172

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

50 microgram PF-06273588 intravenous

Subjects will receive a single intravenous microdose of PF-06273588 in period one

Group Type EXPERIMENTAL

PF-06273588

Intervention Type DRUG

Intravenous, 50 microgram, single dose

50 microgram PF-06273588 oral

Subjects will receive a single oral microdose of PF-06273588 in period two

Group Type EXPERIMENTAL

PF-06273588

Intervention Type DRUG

Oral solution, 50 microgram, single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-06273588

Intravenous, 50 microgram, single dose

Intervention Type DRUG

PF-06273588

Oral solution, 50 microgram, single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male subjects between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \> 50 kg (110 lbs).

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* A positive urine drug screen.
* History of regular alcohol consumption exceeding 21 drinks/week for males.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes